Amgen (AMGN) Reiterated at Neutral by Cantor Fitzgerald: Q2 Beat Expected
Tweet Send to a Friend
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $350.00 price target on Amgen (NASDAQ: AMGN).The ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
